trial · primary record
Venetoclax
Lymphoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 155 |
| Primary completion | 2027-12-01 |
| Primary endpoint | Number and grade of adverse events |
| Registry ID | NCT03223610 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:23.660Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03223610
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- VENETOCLAX · approval
- Venetoclax · compound